An Open-Label Study of Nefazodone Treatment of Major Depression in Patients with Congestive Heart Failure

Canadian Journal of Psychiatry

Volumn 48, Issue 10, 2003, Pages 695-701

  Lespérance, François ^a,b   Frasure Smith, Nancy ^a,b,c,d   Laliberté, Marc André ^a,d   White, Michel ^a,d   Lafontaine, Sylvain ^a,e   Calderone, Angelino ^d   Talajic, Mario ^a,d   Rouleau, Jean L ^a,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Congestive heart failure; Heart rate; Heart rate variability; Major depression; Nefazodone; Norepinephrine; QTc interval

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEFAZODONE; NITRATE; NORADRENALIN; PLACEBO; POTASSIUM; WARFARIN;

ADRENERGIC ACTIVITY; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON SCALE; HEADACHE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; IMPOTENCE; MAJOR DEPRESSION; MALE; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; NAUSEA; NIGHTMARE; NORADRENALIN BLOOD LEVEL; PANIC; PATIENT COMPLIANCE; PSYCHOLOGIC TEST; QT INTERVAL; QUALITY OF LIFE; SEDATION; SIDE EFFECT; STATE TRAIT ANXIETY INVENTORY; VERTIGO; VISUAL IMPAIRMENT;

EID: 0346874406     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304801009     Document Type: Article

References (31)

1. Ladwig KH, Kieser M, König M, Breithardt G, Borggrefe M. Affective disorders and survival after acute myocardial infarction: results from the Post-Infarction Late Potential Study. Eur Heart J 1991;12:959-64.
2. Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993;270:1819-25.
3. Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005.
4. Lespérance F, Frasure-Smith N, Juneau M, Théroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000;160:1354-60.
5. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627-33.
6. Connerney I, Shapiro PA, McLaughlin JS, Bagiella E, Sloan RP. Relation between depression after coronary artery bypass surgery and 12-month outcome: a prospective study. Lancet 2001;358:1766-71.
7. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, and others. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-56.
8. Glassman AH, Roose SP, Bigger JT, Jr. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993;269:2673-5.
9. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EGV, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:660-5.
10. Shapiro PA, Lespérance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW, and others. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHART Trial). Am Heart J 1999;137:1100-6.
11. Strik JJMH, Honig A, Lousberg R, Lousberg AHP, Cheriex EC, Tuynman-Qua HG, and others. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000;62:783-9.
12. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, and others. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-91.
13. Glassman AH, O'Connor CM, Califf R, Swedberg K, Schwartz P, Bigger JT Jr, and others. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.
14. Rouleau J-L, Packer M, Moyé L, DeChamplain JR, Bichet D, Klein M, and others. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583-91.
15. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, and others. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
16. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
17. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, and others. Sympathetic nervous system activity in major depression-basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1993;50:1-12.
18. Roy A, Pickar D, de Jong J, Karoum F, Linnoila M. Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine: relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988;45:849-57.
19. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, and others. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001;104:2024-8.
20. Vanhoutte P, Amery A, Birkenhäger W, Breckenridge A, Bühler F, Distler A, and others. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 1988;11:111-33.
21. Hedner T, Andersson OK, Pettersson A, Persson B. Cardiovascular effects of ketanserin during cold pressure and during isometric and dynamic exercise in hypertensive patients. J Cardiovasc Pharmacol 1987;10(Suppl 3):S73-S77.
22. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV axis I disorders. New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
23. Hamilton MA. Rating Scale for Depression. J Neurol, Neurosurg Psychiatry 1960;23:56-62.
24. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
25. Spitzer RL, Williams JBW, Kroenke K, Linzer M, deGruy III FV, Hahn SR, and others. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 Study. JAMA 1994;272:1749-56.
26. Nemeroff CB, DeVane L, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
27. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory (form Y). Palo Alto (CA): Consulting Psychologists Press Inc; 1983.
28. Rector T, Cohn JN, the Pimobendan Multicenter Research Group. Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-25.
29. Rouleau JL, de Champlain J, Klein M, Bichet D, Moyé L, Packer M, and others. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993;22:390-8.
30. The ENRICHD investigators. Enhancing recovery in coronary heart disease (ENRICHD): Baseline characteristics. Am J Cardiol 2001;88:316-22.
31. Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirlin P, and others. Effect of long-term enelapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 1995;75:1151-7.